Home / Companies / Results / Alembic Pharma's Q2 net profit up 35% at Rs 333 cr on strong domestic biz

Alembic Pharma's Q2 net profit up 35% at Rs 333 cr on strong domestic biz

Consolidated total income up 17.65 per cent at Rs 1,460.32 cr in Q2 of FY21 as against Rs 1.241.23 cr a year ago

cash, currency, notes, funds, investment, shares, growth, profit, loss, tax, money, income, earnings

Premium

The company's overall international formulations grew by 21 per cent to stand at Rs 779 crore during the quarter

2 min read Last Updated : Oct 22 2020 | 6:20 PM IST

Vadodara-based Alembic Pharmaceuticals Limited has registered a 35 per cent growth in its consolidated profit after tax (PAT) for the quarter ended September 30, 2020. As against a net profit of Rs 246.27 crore in Q2 of previous fiscal 2019-20, the company posted a PAT of Rs 333.37 crore in the second quarter of current fiscal 2020-21.

The company's consolidated total income rose by 17.65 per cent to stand at Rs 1,460.32 crore in Q2 of FY21 as against Rs 1.241.23 crore in Q2 of FY'20.

While Alembic Pharma's international formulations business and active pharmaceutical ingredients (API) business did well during the

Topics : Alembic Pharmaceuticals Q2 results

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in